| Biomarker ID | 361 |
| PMID | 18593988 |
| Year | 2008 |
| Biomarker | Osteopontin |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Recurrent Group (Recurrent Group: 203.2 ± 78.4; Non Recurrent Group: 127.76 ± 76.6) |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 1.01 (95% CI: 1.00-1.01) |
| Effect on Pathways | Pathways Include:-Alpha-V beta-3 integrin/OPN pathway,TWEAK regulation of gene expression,Osteopontin signaling,Osteoclast signaling,Beta-3 integrin cell surface interactions |
| Experiment | Reccurance Free Survival Vs Recurrance in 5 years |
| Type of Biomarker | Prognostic |
| Cohort | 103 prostatectomy specimens were obtained with a 72 month follow up period. 53 cases of Biochemical reccurrances and 50 patients with no recurrance. |
| Senstivity | 75.5 (Monte Carlo Cross Validation: 75.9 ± 4.2) |
| Specificity | 76 (Monte Carlo Cross Validation: 75.6 ± 3.9) |
| AUC | 0.767 |
| Accuracy | 75.7 ((Monte Carlo Cross Validation: 75.9 ± 2.8) |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SPP1 |